Zentalis appoints Diana Hausman as CMO, Kyle Rasbach as CBO; receives Nasdaq notice on audit committee

Zentalis Pharmaceuticals, Inc.

Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.
Kyle Rasbach appointed CBO; formerly portfolio manager at Eventide Asset Management.
Dr. Hausman resigned from Board and Audit Committee, causing Nasdaq audit committee independence non-compliance.
Company has 180 days (by July 17, 2024) to appoint a third independent director to regain compliance.
Dr. Brownstein receives severance: 10 months base salary + 2023 & prorated 2024 target bonuses, 12 months COBRA.

item 3.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diana Hausman

Chief Medical Officer

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-01-19
Filed: January 25, 2024, 6:59 PM ET

On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024

Departed

Carrie Brownstein

Chief Medical Officer

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-01-19
Successor: Diana Hausman
Filed: January 25, 2024, 6:59 PM ET

Dr. Brownstein stepped down for personal reasons.

Departed

Diana Hausman

Director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-01-19
Filed: January 25, 2024, 6:59 PM ET

Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Diana Hausman was appointed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carrie Brownstein departed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..

Action: stepped down
Role: Chief Medical Officer

Exact text from the filing

Dr. Brownstein stepped down for personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Diana Hausman resigned as Director at Zentalis Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.